@misc{misc2e51560e,
title   = {Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study},
author = {Robak, Tadeusz and Huang, Huiqiang and Jim, Jie and Shu, Jun and Liu, Ting and Samailova, Olga S. and Pereira, Juliana and Pylypenko, Halyna and Verhoef, Gregor and Siritanaratkul, Noppadol and Osmanov, Evgenii A. and Alexeeva, Julia and Mayer, Jiri and Hong, Xiaonan and Maeda, Yoshiharu and Rooney, Brendan and van de Velde, Helgi and Cavalli, Franco},
year = {2014},
booktitle   = {Annual Meeting and Exposition / ASH}
}